Newcastle disease virus (NDV or AOaV-1) is an avian paramyxovirus that typically causes only mild, self-limiting disease in humans. Here, we report fatal neuroinvasive AOaV-1 infection in a patient with multiple myeloma receiving maintenance therapy with teclistamab, daratumumab, and lenalidomide following frontline te...
Christina Krueger, C. Schaefers, T. Guenther et al.· Acta Neuropathologica· 0 citations
Primary thyroid diffuse large B-cell lymphoma (DLBCL) is a rare subset of primary extranodal DLBCL. Thus, there are limited evidence-based specific recommendations regarding its diagnosis and treatment. We present a case report of a patient with relapsed primary thyroid DLBCL, followed by a focused literature review co...
K. Kirkgöz, K. Weisel, Carsten Bokemeyer et al.· Annals of Hematology· 0 citations
In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in transplant-ineligible newly diagnosed multiple myelom...
T. Facon, G. Cook, S. Usmani et al.· Leukemia· 0 citations
The BELI(E)VE trial aims to establish a novel personalized therapeutic approach for a specific subset of MM patients by combining belantamab mafodotin and venetoclax, potentially inducing deep and durable remissions in t(11;14)-positive RRMM patients.
C. Schaefers, Cyrus Khandanpour, M. Hänel et al.· BMC Cancer· 0 citations
(GPRC5D) is a leading immunotherapy target in multiple myeloma (MM), with diverse GPRC5D-targeting agents — including T-cell engagers (TCE), antibody – drug conjugates
Ricardo Ahrens, K. Ahrens, Maximilian Al-Bazaz et al.· Blood Cancer Journal· 0 citations
Biparatopic targeting of CD38 using CD38-STARs represents a promising strategy for the treatment of MM, including the rare cases in which daratumumab fails to bind due to CD38 mutations.
H. Risch, A. J. Gebhardt, Niklas Hagen et al.· Frontiers in Immunology· 0 citations
Deeper pre-infusion response was associated with significantly lower toxicity after BCMA-directed CAR-T therapy, identifying pre-infusion disease control as a potentially modifiable determinant of toxicity.
J. Artzenroth, R. Kosch, Maximilian Al-Bazaz et al.· Transplantation and Cellular...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.